Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy

NCT01287585 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

636

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: ADI-PEG 20 (arginine deiminase formulated with polyethylene glycol)
DRUG: Placebo
OTHER: Best Supportive Care

Sponsor

Polaris Group